Duke to host private meeting with payers and biopharma on how to pay for Alzheimer's drugs
How is the US going to restrict the use of Biogen’s new Alzheimer’s drug so Medicare doesn’t go bankrupt before the end of the decade? That’s the multi-billion dollar question that the federal government, payers, and clinicians will need to hash out as the more than 6 million people with Alzheimer’s turn to Aduhelm as a potential option.
But with scant details on how those coverage determinations will be made, it’s unclear how exactly the Centers for Medicare and Medicaid Services will pay for Aduhelm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.